454 Enabling Technologies for Immunotherapy Development


Description:
This session will focus on technologies that support the development of novel immunotherapies. Topics of interest include but are not limited to genome editing in primary immune cells, in vivo imaging, and high-throughput protein engineering for immunotherapy applications.

Sponsor:
Immunotherapy


Chair:
Arnab Mukherjee
Assistant Professor
University of California Santa Barbara
Chemical Engineering
Santa Barbara, CA
Phone Number: (805) 893-5137
Email: arnabm@engineering.ucsb.edu


Papers:
454a
Eradication of Primary and Cancer Stem Cells By Chemically Self-Assembled Nanoring Targeted T-Cells
Carston R. Wagner, University of Minnesota; Jacob R. Petersburg, University of Minnesota; Clifford M. Csizmar, University of Minnesota
454b
Inhibition of Peanut Induced Mast Cell Degranulation By Designing Covalent Heterobivalent Inhibitors
Jaeho Shin, University of Notre Dame; Peter Deak, University of Notre Dame; Baksun Kim, University of Notre Dame; Amina Abdul Qayum, IUPUI; Girish Vitalpur, Indiana University School of Medicine; Kirsten Kloepfer, Indiana University School of Medicine; Tanyel Kiziltepe, University of Notre Dame; Mark Kaplan, Indiana University; Basar Bilgicer, University of Notre Dame
454c
Remote Control of Engineered T Cells Using Photothermal Pulses
Ian Miller, Georgia Institute of Technology; Marielena Gamboa Castro, Georgia Institute of Technology; Lee-Kai Sun, Georgia Institute of Technology; Jason Weis, Georgia Institute of Technology; Gabriel Kwong, Georgia Institute of Technology
454d
Serum Antibody Profiling of Nivolumab/Azacytidine-Treated Acute Myeloid Leukemia Patients Via High-Throughput Sequencing of Peptide Phage-Display Library
Jay R Adolacion, University of Houston; Richard C. Willson, University of Houston; Navin Varadarajan, University of Houston
Break
454e
Yeast Surface Display Techniques Enhance Development of Chimeric Antigen Receptors for Hematologic Malignancies
Lawrence A. Stern, Beckman Research Institute of the City of Hope; Laura Lim, Beckman Research Institute of the City of Hope; Christian Huynh, Beckman Research Institute of the City of Hope; Marissa M. Del Real, Beckman Research Institute of the City of Hope; Lindsay O'Brien, Beckman Research Institute of the City of Hope; Wen-Chung Chang, Beckman Research Institute of the City of Hope; Michalina Silva, Beckman Research Institute of the City of Hope; Brenda Aguilar, Beckman Research Institute of the City of Hope; John C. Williams, Beckman Research Institute of the City of Hope; L. Elizabeth Budde, Beckman Research Institute of the City of Hope; Xiuli Wang, Beckman Research Institute of the City of Hope; Christine E. Brown, Beckman Research Institute of the City of Hope; Stephen J. Forman, Beckman Research Institute of the City of Hope
454f
Efficient Incorporation of Matrix Protein M2 into Influenza Virus-like Particles (VLPs) for Improved Vaccine Manufacturing and Efficacy
Andrew Zak, University of Michigan; Brett Hill, University of Michigan; Syed Rizvi, University of Michigan; Fei Wen, University of Michigan
454g
Cytokine-like Regulation of T-Cell Fate Mediated By Tryptophan-Derived Microbiota Metabolites
Arul Jayaraman, Texas A&M University
Abstract Submissions Closed
See more of this Group/Topical: Topical Conference: Immunotherapy
<< Previous Session | Next Session >>